Previous close | 11.98 |
Open | 11.75 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 11.75 - 11.75 |
52-week range | 7.03 - 15.87 |
Volume | |
Avg. volume | 1,883 |
Market cap | 14.032B |
Beta (5Y monthly) | 1.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.50 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 28 Nov 2017 |
1y target est | N/A |
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under